Russ Barton spent his career of over 38 years at Eli Lilly and Company and served for the last 10 years as Director of Operations for the Global AD team. In that capacity, he was accountable for clinical and program operations in Alzheimer’s disease. He joined AgeneBio as Director of Clinical Operations for the AGB101 HOPE4MCI program with Phase 2b now underway.
Current role